---
reference_id: "PMID:30999998"
title: "Vascular Ehlers-Danlos Syndrome: Long-Term Observational Study."
authors:
- Frank M
- Adham S
- Seigle S
- Legrand A
- Mirault T
- Henneton P
- Albuisson J
- Denarié N
- Mazzella JM
- Mousseaux E
- Messas E
- Boutouyrie P
- Jeunemaitre X
journal: J Am Coll Cardiol
year: '2019'
doi: 10.1016/j.jacc.2019.01.058
content_type: abstract_only
---

# Vascular Ehlers-Danlos Syndrome: Long-Term Observational Study.
**Authors:** Frank M, Adham S, Seigle S, Legrand A, Mirault T, Henneton P, Albuisson J, Denarié N, Mazzella JM, Mousseaux E, Messas E, Boutouyrie P, Jeunemaitre X
**Journal:** J Am Coll Cardiol (2019)
**DOI:** [10.1016/j.jacc.2019.01.058](https://doi.org/10.1016/j.jacc.2019.01.058)

## Content

1. J Am Coll Cardiol. 2019 Apr 23;73(15):1948-1957. doi: 
10.1016/j.jacc.2019.01.058.

Vascular Ehlers-Danlos Syndrome: Long-Term Observational Study.

Frank M(1), Adham S(2), Seigle S(3), Legrand A(4), Mirault T(5), Henneton P(6), 
Albuisson J(4), Denarié N(3), Mazzella JM(3), Mousseaux E(7), Messas E(5), 
Boutouyrie P(8), Jeunemaitre X(9).

Author information:
(1)AP-HP, Hôpital Européen Georges Pompidou, Département de Génétique, Centre de 
Référence des Maladies Vasculaires Rares, Paris, France; INSERM, U 970, Paris 
Centre de Recherche Cardiovasculaire-PARCC, Paris, France.
(2)AP-HP, Hôpital Européen Georges Pompidou, Département de Génétique, Centre de 
Référence des Maladies Vasculaires Rares, Paris, France; Université Paris 
Sorbonne Cité, Faculté de Médecine Paris Descartes, Paris, France.
(3)AP-HP, Hôpital Européen Georges Pompidou, Département de Génétique, Centre de 
Référence des Maladies Vasculaires Rares, Paris, France.
(4)AP-HP, Hôpital Européen Georges Pompidou, Département de Génétique, Centre de 
Référence des Maladies Vasculaires Rares, Paris, France; INSERM, U 970, Paris 
Centre de Recherche Cardiovasculaire-PARCC, Paris, France; Université Paris 
Sorbonne Cité, Faculté de Médecine Paris Descartes, Paris, France.
(5)AP-HP, Hôpital Européen Georges Pompidou, Département de Génétique, Centre de 
Référence des Maladies Vasculaires Rares, Paris, France; AP-HP, Hôpital Européen 
Georges Pompidou, Service de Médecine Vasculaire, Paris, France.
(6)AP-HP, Hôpital Européen Georges Pompidou, Département de Génétique, Centre de 
Référence des Maladies Vasculaires Rares, Paris, France; Service de Médecine 
Vasculaire, CHU Montpellier, Montpellier, France.
(7)INSERM, U 970, Paris Centre de Recherche Cardiovasculaire-PARCC, Paris, 
France; Université Paris Sorbonne Cité, Faculté de Médecine Paris Descartes, 
Paris, France; AP-HP, Hôpital Européen Georges Pompidou, Service de Radiologie 
Cardiovasculaire, Paris, France.
(8)INSERM, U 970, Paris Centre de Recherche Cardiovasculaire-PARCC, Paris, 
France; Université Paris Sorbonne Cité, Faculté de Médecine Paris Descartes, 
Paris, France; AP-HP, Hôpital Européen Georges Pompidou, Département de 
Pharmacologie, Paris, France.
(9)AP-HP, Hôpital Européen Georges Pompidou, Département de Génétique, Centre de 
Référence des Maladies Vasculaires Rares, Paris, France; INSERM, U 970, Paris 
Centre de Recherche Cardiovasculaire-PARCC, Paris, France; Université Paris 
Sorbonne Cité, Faculté de Médecine Paris Descartes, Paris, France. Electronic 
address: xavier.jeunemaitre@aphp.fr.

Comment in
    J Am Coll Cardiol. 2019 Apr 23;73(15):1958-1960. doi: 
10.1016/j.jacc.2019.02.025.

BACKGROUND: Vascular Ehlers-Danlos syndrome (vEDS) is a rare genetic connective 
tissue disorder secondary to pathogenic variants within the COL3A1 gene, 
resulting in exceptional arterial and organ fragility and premature death. The 
only published clinical trial to date demonstrated the benefit of celiprolol on 
arterial morbimortality.
OBJECTIVES: The authors herein describe the outcomes of a large cohort of vEDS 
patients followed ≤17 years in a single national referral center.
METHODS: All patients with molecularly confirmed vEDS were included in a 
retrospective cohort study. After an initial work-up, patients were treated or 
recommended for treatment with celiprolol (≤400 mg/day) in addition to usual 
care and scheduled for yearly follow-up. vEDS-related events and deaths were 
collected and recorded for each patient.
RESULTS: Between 2000 and 2017, 144 patients (median age at diagnosis 34.5 
years, 91 probands) were included in this study. After a median follow-up of 5.3 
years, overall patient survival was high (71.6%; 95% confidence interval: 50% to 
90%) and dependent on the type of COL3A1 variant, age at diagnosis, and medical 
treatment. At the end of the study period, almost all patients (90.3%) were 
treated with celiprolol alone or in combination. More than two-thirds of 
patients remained clinically silent, despite a large number (51%) with previous 
arterial events or arterial lesions at molecular diagnosis. Patients treated 
with celiprolol had a better survival than others (p = 0.0004). The observed 
reduction in mortality was dose-dependent: the best protection was observed at 
the dose of 400 mg/day versus <400 mg/day (p = 0.003). During the period 
surveyed, the authors observed a statistically significant difference in the 
ratio of hospitalizations for acute arterial events/hospitalizations for regular 
follow-up before and after 2011.
CONCLUSIONS: In this long-term survey, vEDS patients exhibited a low annual 
occurrence of arterial complications and a high survival rate, on which the 
overall medical care seems to have a positive influence.

Copyright © 2019 American College of Cardiology Foundation. Published by 
Elsevier Inc. All rights reserved.

DOI: 10.1016/j.jacc.2019.01.058
PMID: 30999998 [Indexed for MEDLINE]